The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary safety, pharmacokinetics, and pharmacodynamics of duvelisib plus rituximab or obinutuzumab in patients with previously untreated CD20+ follicular lymphoma.
 
Carla Casulo
No Relationships to Disclose
 
Eric D. Jacobsen
Honoraria - Seagen
Consulting or Advisory Role - Seagen
Research Funding - Seagen
 
Koen Van Eygen
Honoraria - Janssen-Cilag
 
Houston Eccleston Holmes
Stock and Other Ownership Interests - Medfusion
Speakers' Bureau - Onyx
Research Funding - Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst)
 
Jan P. Lemmens
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche
 
Kerstin Allen
Employment - Infinity Pharmaceuticals
Stock and Other Ownership Interests - Infinity Pharmaceuticals
 
Lori Steelman
Employment - Infinity Pharmaceuticals
Stock and Other Ownership Interests - Infinity Pharmaceuticals
 
Veronica Campbell
Employment - Infinity Pharmaceuticals
 
Jylle Nevejans
Employment - Infinity Pharmaceuticals
 
Joseph Pearlberg
Employment - Infinity Pharmaceuticals
 
Andre Goy
Honoraria - Acerta Pharma; Celgene; Pharmacyclics; Takeda
Consulting or Advisory Role - Acerta Pharma; Celgene; Infinity Pharmaceuticals; Pharmacyclics; Takeda
Speakers' Bureau - Pharmacyclics; Takeda
Research Funding - Clinical Trials Through Institution